Medicare Increases Payment Rates for Most Physicians

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 1
Volume 10
Issue 1

WASHINGTON-Physicians will receive an average 4.5% increase in Medicare payment rates in 2001, the Health Care Financing Administration (HCFA) announced. Increases will range from nothing to 12%, depending on specialty.

WASHINGTON—Physicians will receive an average 4.5% increase in Medicare payment rates in 2001, the Health Care Financing Administration (HCFA) announced. Increases will range from nothing to 12%, depending on specialty.

Those paid under the classification hematology/oncology will receive a 6% payment increase; radiation oncologists will get 3%; and internal medicine physicians, 5%. Neurosurgeons received 1%, general surgeons, 2%; and obstetricians/gynecologists and urologists each received 6%.

Medicare payments will vary for specific services because the agency is in the midst of implementing a new payment system for physician practice expenses based on the resources involved in treating patients rather than on physician’s historical charges.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content